Sav Aydin, Rotondo Fabio, Syro Luis V, Di Ieva Antonio, Cusimano Michael D, Kovacs Kalman
Department of Pathology, Acibadem University, School of Medicine, Kerem Aydinlar Yerleskesi, Icerenkoy Mahallesi, Kayisdagi Caddesi, No: 32, Atasehir, Istanbul, Turkey.
Division of Pathology, Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Endocrinol Metab Clin North Am. 2015 Mar;44(1):99-104. doi: 10.1016/j.ecl.2014.10.008. Epub 2014 Nov 4.
Aggressive pituitary adenomas have a high risk of recurrence, a lack of therapeutic response, and resistance to conventional treatment. So far, no satisfactory biomarkers are available for predicting their behavior. Some specific pituitary adenoma histotypes are more prone to follow an aggressive behavior. Pituitary carcinomas are rare and show cerebrospinal and/or systemic metastasis. They have worse prognosis than aggressive adenomas, and radiation is of limited use in their treatment.
侵袭性垂体腺瘤具有高复发风险、治疗反应缺乏以及对传统治疗耐药的特点。到目前为止，尚无令人满意的生物标志物可用于预测其行为。一些特定的垂体腺瘤组织学类型更容易表现出侵袭性行为。垂体癌罕见，可发生脑脊液和/或全身转移。它们的预后比侵袭性腺瘤更差，放疗在其治疗中的作用有限。
